References
Rovira J. Transparency of economic evaluations of health technologies. Pharmacoeconomics 2008; 26 (3): 181–3
Hill S. Transparency in economic evaluations. Pharmacoeconomics 2005; 23 (10): 967–9
Bell CM, Urbach DR, Ray JG, et al. Bias in published cost effectiveness studies: systematic review. BMJ 2006; 332 (7543): 699–703
Drummond MF. A reappraisal of economic evaluation of pharmaceuticals. Pharmacoeconomics 1998; 14 (1): 1–9
Hill SR, Mitchell AS, Henry DA. Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA 2000; 283 (16): 2116–21
Wager E, Middleton P. Technical editing of research reports in biomedical journals. Cochrane Database Syst Rev 2007 Apr 18; (2): MR000002
Carswell CI, McWilliams P. It’s a matter of perspective [poster]. In press
Carswell CI, Paladino JA. Reporting pharmacoeconomic evaluations. Pharmacoeconomics 2005; 23 (11): 1073
Haycox A. When NICE says no! Pharmacoeconomics 2007; 25 (12): 995–6
Getsios D, Migliaccio-Walle K, Caro JJ. NICE cost-effectiveness appraisal of cholinesterase inhibitors: was the right question posed? Were the best tools used? Pharmacoeconomics 2007; 25 (12): 997–1006
Godlee F. Making reviewers visible: openness, accountability, and credit. JAMA 2002; 287 (21): 2762–5
BMJ Publishing Group, Ltd. Peer review process [online]. Available from URL: http://resources.bmj.com/bmj/authors/article-submission/peer-review-process/peer-review-process?grp=l [Accessed 2008 Jan 21]
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Carswell, C.I., Paladino, J.A. Meandering Down the Road to Transparency. Pharmacoeconomics 26, 179–180 (2008). https://doi.org/10.2165/00019053-200826030-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-200826030-00001